BioSpace News Archive

Galmed Pharmaceuticals Ltd. announced today results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.

Aurinia Pharmaceuticals Inc. today announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease.

Developed in collaboration with Teva Pharmaceuticals, mdc-IRM, a risperidone extended-release injectable suspension for the treatment of patients with schizophrenia

Zealand Pharma A/S today announced it will present preclinical data from its amylin analogue, ZP8396 at the Obesity Society Annual Meeting, to be held virtually during ObesityWeek® Interactive, an online conference taking place in the week of November 1-5, 2021.

7 Hills Pharma LLC today announced that it has successfully completed its Phase I clinical trial to evaluate 7HP349, their lead molecule.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that members of management are scheduled to participate in three upcoming investor conferences.

908 Devices Inc. announced at the American Society for Mass Spectrometry (ASMS) conference today a new Oligos assay kit for its ZipChip device that enables fast and accurate identification and quantitation of oligonucleotides.

Antibe Therapeutics Inc. is pleased to provide further detail on otenaproxesul’s development plan for acute pain indications.

Kaleido Biosciences, Inc. today reported financial results for the third quarter ended September 30, 2021.

Graybug Vision, Inc. announced two clinical data presentations at the American Academy of Ophthalmology 2021 Annual Meeting to be held on November 12-15, 2021 in New Orleans, Louisiana, as well as a company presentation at the Eyecelerator@AAO 2021 event on November 11, 2021: